Cinacalcet therapy suppressed C-reactive protein levels (from 2.5 ± 0.6 to 0.8 ± 0.5 mg/L), suggesting that inflammatory burden in CKD-MBD may be benefited after optimizing parathyroid–bone axis. This evidence concerns the gene CRP and chronic kidney disease.